Sphera Funds Management’s Eledon Pharmaceuticals ELDN Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q3
$3.52M Buy
1,392,187
+201,000
+17% +$675K 0.5% 69
2026
Q2
$4.69M Sell
1,191,187
-580,944
-33% -$2.11M 0.61% 53
2026
Q1
$5.46M Sell
1,772,131
-360,000
-17% -$848K 0.87% 42
2025
Q4
$3.22M Buy
2,132,131
+851,898
+67% +$2.02M 0.62% 58
2025
Q3
$3.32M Sell
1,280,233
-679,377
-35% -$1.99M 0.7% 48
2025
Q2
$5.31M Sell
1,959,610
-347,509
-15% -$1.04M 1.25% 27
2025
Q1
$7.82M Sell
2,307,119
-244,500
-10% -$1.01M 1.8% 14
2024
Q4
$10.5M Buy
2,551,619
+1,254,298
+97% +$4.94M 1.9% 11
2024
Q3
$3.23M Buy
1,297,321
+300
+0% +$803 0.51% 57
2024
Q2
$3.42M Buy
+1,297,021
New +$3.1M 0.47% 62
2015
Q2
– Sell
-903
Closed -$1.65M – 142
2015
Q1
$1.65M Sell
903
-47
-5% -$104K 0.17% 117
2014
Q4
$2.27M Sell
950
-470
-33% -$1.12M 0.39% 82
2014
Q3
$3.48M Buy
+1,420
New +$4.04M 0.43% 53

Other funds holding ELDN

Sphera Funds Management's ELDN Position: Q3 2026 in Review

Sphera Funds Management increased its Eledon Pharmaceuticals (ELDN) stake by 17% in Q3 2026, buying an estimated $675K and bringing the position to 1,392,187 shares worth $3.52M. The position accounts for 0.5% of the portfolio, ranked #69.

Sphera Funds Management first reported a position in ELDN in Q3 2014 and has held it in 13 quarters since. The position peaked at $10.5M in Q4 2024. 155 funds tracked by Wall St. Rank hold ELDN as of Q3 2026.

  • Sphera Funds Management held 1,392,187 shares of Eledon Pharmaceuticals worth $3.52M as of Q3 2026.
  • Sphera Funds Management bought 201,000 Eledon Pharmaceuticals shares in Q3 2026, an estimated $675K.
  • Eledon Pharmaceuticals made up 0.5% of Sphera Funds Management's portfolio in Q3 2026, its #69 holding.
  • Sphera Funds Management first reported a position in Eledon Pharmaceuticals in Q3 2014 and has held it in 13 quarters since.
  • Sphera Funds Management's Eledon Pharmaceuticals position peaked at $10.5M in Q4 2024.
  • 155 funds tracked by Wall St. Rank held Eledon Pharmaceuticals as of Q3 2026.

Based on Sphera Funds Management's 13F filing for Q3 2026, filed 16 Nov 2026.